Compare BBUC & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBUC | ADPT |
|---|---|---|
| Founded | 2022 | 2009 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.5B |
| IPO Year | 2015 | 2019 |
| Metric | BBUC | ADPT |
|---|---|---|
| Price | $28.38 | $26.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $37.38 | $30.21 |
| AVG Volume (30 Days) | 272.3K | ★ 2.0M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.87% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,976,000.00 |
| Revenue This Year | N/A | $5.03 |
| Revenue Next Year | N/A | $22.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $24.80 | $12.00 |
| 52 Week High | $38.25 | $30.74 |
| Indicator | BBUC | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 63.51 | 51.10 |
| Support Level | $24.80 | $23.76 |
| Resistance Level | $32.12 | $30.35 |
| Average True Range (ATR) | 0.78 | 1.48 |
| MACD | 0.22 | 0.25 |
| Stochastic Oscillator | 79.58 | 53.35 |
Brookfield Business Corp is the operator of vital industrial and business services operations. The company focuses on acquiring market businesses for value, execute its operational improvement plans to increase cash flows and recycle capital to compound long-term growth. Geographically, it derives maximum revenue from the United States, and the rest from Europe, Brazil, Australia, Canada, and others. It operates in four segments within particular sectors namely: business services, infrastructure services, industrials, and corporate. The company derives maximum revenue from Industrials segment engaged in energy storage operations, engineered components manufacturing operations, water and wastewater operations, electric heat tracing systems manufacturer, and other industrials operations.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.